Back to Results
First PageMeta Content
Docetaxel / Ovarian cancer / Renal cell carcinoma / Metastasis / Antibody-drug conjugate / Cyclacel / Medicine / Bevacizumab / CRLX101


The team at Cerulean (NASDAQ: CERU) is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting™ Platform to create a portfolio of nanoparticle-drug conjugates (NDCs) designe
Add to Reading List

Document Date: 2015-06-01 11:12:23


Open Document

File Size: 637,28 KB

Share Result on Facebook
UPDATE